Stem definition | Drug id | CAS RN |
---|---|---|
clofibrate derivatives, peroxisome proliferator activated receptor-alpha(PPAR-alpha) agonists | 362 | 41859-67-0 |
Dose | Unit | Route |
---|---|---|
0.60 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 40 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 23.69 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 99 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 1, 1978 | YEAR INTRODUCED |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Diverticular perforation | 77.09 | 26.28 | 18 | 1459 | 3150 | 50600497 |
Vascular stent stenosis | 68.37 | 26.28 | 12 | 1465 | 498 | 50603149 |
Coronary artery thrombosis | 65.53 | 26.28 | 13 | 1464 | 1054 | 50602593 |
Carotid arteriosclerosis | 60.66 | 26.28 | 12 | 1465 | 959 | 50602688 |
Arterial stenosis | 60.51 | 26.28 | 11 | 1466 | 558 | 50603089 |
Helicobacter gastritis | 55.70 | 26.28 | 12 | 1465 | 1458 | 50602189 |
Cor pulmonale acute | 45.81 | 26.28 | 8 | 1469 | 322 | 50603325 |
Hepatic cyst | 42.38 | 26.28 | 12 | 1465 | 4481 | 50599166 |
Cardiorenal syndrome | 41.32 | 26.28 | 8 | 1469 | 571 | 50603076 |
Coronary artery stenosis | 38.40 | 26.28 | 11 | 1466 | 4278 | 50599369 |
Acute coronary syndrome | 33.69 | 26.28 | 12 | 1465 | 9362 | 50594285 |
Coronary artery occlusion | 32.34 | 26.28 | 11 | 1466 | 7492 | 50596155 |
Glycosylated haemoglobin decreased | 30.36 | 26.28 | 6 | 1471 | 476 | 50603171 |
Hallucinations, mixed | 30.02 | 26.28 | 9 | 1468 | 4094 | 50599553 |
Thalamus haemorrhage | 28.95 | 26.28 | 6 | 1471 | 604 | 50603043 |
Obstruction gastric | 26.97 | 26.28 | 6 | 1471 | 843 | 50602804 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pancreatitis acute | 40.08 | 24.43 | 22 | 1680 | 24363 | 29548462 |
Hypertriglyceridaemia | 38.77 | 24.43 | 15 | 1687 | 7460 | 29565365 |
Hepatic function abnormal | 32.76 | 24.43 | 23 | 1679 | 39236 | 29533589 |
Periorbital haemorrhage | 28.28 | 24.43 | 5 | 1697 | 107 | 29572718 |
Diabetes mellitus | 25.71 | 24.43 | 20 | 1682 | 39811 | 29533014 |
Blood creatine phosphokinase increased | 25.35 | 24.43 | 20 | 1682 | 40624 | 29532201 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Diverticular perforation | 53.80 | 23.20 | 17 | 3310 | 5196 | 64490209 |
Vascular stent stenosis | 50.25 | 23.20 | 12 | 3315 | 1297 | 64494108 |
Hypertriglyceridaemia | 47.99 | 23.20 | 19 | 3308 | 11186 | 64484219 |
Coronary artery thrombosis | 45.36 | 23.20 | 13 | 3314 | 2856 | 64492549 |
Carotid arteriosclerosis | 44.74 | 23.20 | 12 | 3315 | 2067 | 64493338 |
Arterial stenosis | 44.49 | 23.20 | 11 | 3316 | 1374 | 64494031 |
Helicobacter gastritis | 44.07 | 23.20 | 12 | 3315 | 2188 | 64493217 |
Hepatic function abnormal | 43.97 | 23.20 | 32 | 3295 | 64281 | 64431124 |
Acute kidney injury | 42.79 | 23.20 | 80 | 3247 | 449160 | 64046245 |
Pancreatitis acute | 40.38 | 23.20 | 26 | 3301 | 42829 | 64452576 |
Cor pulmonale acute | 36.19 | 23.20 | 8 | 3319 | 614 | 64494791 |
Rhabdomyolysis | 35.95 | 23.20 | 33 | 3294 | 91693 | 64403712 |
Hepatic cyst | 33.81 | 23.20 | 12 | 3315 | 5228 | 64490177 |
Cardiorenal syndrome | 30.64 | 23.20 | 8 | 3319 | 1242 | 64494163 |
Hyperuricaemia | 29.25 | 23.20 | 13 | 3314 | 10178 | 64485227 |
Blood creatine phosphokinase increased | 28.83 | 23.20 | 24 | 3303 | 58534 | 64436871 |
Renal impairment | 26.98 | 23.20 | 34 | 3293 | 134983 | 64360422 |
Acute coronary syndrome | 26.71 | 23.20 | 15 | 3312 | 19295 | 64476110 |
Periorbital haemorrhage | 25.62 | 23.20 | 5 | 3322 | 208 | 64495197 |
Glycosylated haemoglobin decreased | 25.48 | 23.20 | 6 | 3321 | 610 | 64494795 |
Coronary artery stenosis | 24.95 | 23.20 | 12 | 3315 | 11236 | 64484169 |
Cerebral infarction | 24.85 | 23.20 | 19 | 3308 | 41025 | 64454380 |
Interstitial lung disease | 23.43 | 23.20 | 27 | 3300 | 97705 | 64397700 |
None
Source | Code | Description |
---|---|---|
ATC | C10AB02 | CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN Fibrates |
MeSH PA | D000963 | Antimetabolites |
MeSH PA | D000960 | Hypolipidemic Agents |
MeSH PA | D057847 | Lipid Regulating Agents |
CHEBI has role | CHEBI:35679 | antilipemic drugs |
CHEBI has role | CHEBI:35703 | Xenobiotic |
CHEBI has role | CHEBI:78298 | environmental contaminants |
CHEBI has role | CHEBI:176497 | geroprotectors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypercholesterolemia | indication | 13644009 | |
Hyperlipidemia | indication | 55822004 | DOID:1168 |
End stage renal disease | contraindication | 46177005 | DOID:784 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 3.71 | acidic |
pKa2 | 12.78 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Peroxisome proliferator-activated receptor alpha | Nuclear hormone receptor | AGONIST | EC50 | 4.30 | IUPHAR | IUPHAR | |||
3-hydroxy-3-methylglutaryl-coenzyme A reductase | Enzyme | INHIBITOR | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||||
Lipoprotein lipase | Enzyme | WOMBAT-PK | |||||||
Fatty acid-binding protein, intestinal | Cytosolic other | Ki | 4.48 | CHEMBL | |||||
Peroxisome proliferator-activated receptor delta | Nuclear hormone receptor | EC50 | 4.45 | CHEMBL | |||||
Peroxisome proliferator-activated receptor gamma | Nuclear hormone receptor | EC50 | 4.18 | WOMBAT-PK | |||||
Fatty acid-binding protein, liver | Unclassified | Ki | 4.35 | CHEMBL |
ID | Source |
---|---|
N0000166742 | NUI |
D01366 | KEGG_DRUG |
1525 | RXNORM |
C0005330 | UMLSCUI |
CHEBI:47612 | CHEBI |
PEM | PDB_CHEM_ID |
CHEMBL264374 | ChEMBL_ID |
DB01393 | DRUGBANK_ID |
D001629 | MESH_DESCRIPTOR_UI |
39042 | PUBCHEM_CID |
2668 | IUPHAR_LIGAND_ID |
3968 | INN_ID |
Y9449Q51XH | UNII |
003937 | NDDF |
319937007 | SNOMEDCT_US |
396025003 | SNOMEDCT_US |
None